A combined responder analysis of tradipitant demonstrates significant improvements in itch and disease severity

Atopic dermatitis (AD) is characterized by skin lesions and pruritus not relieved by scratching. The challenge for current therapies is to treat both of these characteristic disease symptoms. Many of the currently available therapies improve AD through clearing of the skin by targeting improvement in lesion severity. Targeting AD improvement through reduction in pruritus remains a significant unmet medical need. Tradipitant, a novel neurokinin-1 receptor antagonist, is a possible therapy that could improve AD through reduction in pruritus.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research